Ultra Flora MetaControl have been shown to or may:
Provides metabolic benefits including reduced Body Mass Index (BMI), reduction in total cholesterol and Low Density Lipoprotein (LDL).
Improves weight management including total and abdominal fat mass, waist circumference and reduced energy intake.
Clinical Benefits:
Recent microbiome research has established a potential correlation between body weight and the microbiome. DNA analysis has shown that obese subjects may have a different microbiome composition to lean subjects. Gut bacterial composition is able to influence how energy is stored, as well as influence glycaemic control and satiety hormones. Specific probiotics can be a useful adjunct to dietary programs to control weight, metabolic markers and body composition.
Weight control and body composition: Bifidobacterium animalis ssp lactis (B-420™) has a growing body of human and animal research, including a 2016 clinical trial. A 6 month study of 225 non-dieting, overweight people (predominantly women aged 40+) took 10 billion CFU B-420™ daily (with or without dietary fibre) or placebo. Both B-420™ groups showed significant improvements in fat mass, abdominal fat, waist circumference and lean muscle mass, as well as an overall reduction in calorie consumption. Pre-clinical animal and in vitro research on B-420™ has demonstrated reduced weight gain, improved glycaemic response, reduced zonulin levels (a marker of intestinal permeability), improved tight junction integrity, and protection against E. coli-induced damage; decreasing gut inflammation and the consequential impairment in insulin sensitivity.
Cardiometabolic markers can also be influenced by probiotics. A 2016 study on 51 adults with metabolic syndrome showed that Bifidobacterium animalis ssp lactis (HN019™) reduced BMI, total cholesterol (TC) and low density lipoprotein (LDL). The proposed mechanism is associated with prevention of cholesterol absorption by the intestinal tract into the blood stream, by aiding the assimilation of cholesterol during bacterial multiplication and cholesterol binding, and to improve liver metabolism through increased short chain fatty acid (SCFA) production, inhibiting HMG Co-A reductase. Mechanistically, it has been shown to reduce proinflammatory cytokines TNF-α and IL-6, which are associated with the development of obesity.
*27.2 Billion CFU daily of HN019™equivalent to two capsules
Directions:
Adults: Take 1 capsule daily.
Storage:
Store at 2°C to 8°C (Refrigerate. Do not freeze.)
Warnings:
As a precaution: Safety has not been conclusively established during pregnancy. Practitioner discretion is advised when prescribing for use in pregnancy due to the following cautions:
Pre-eclampsia: A meta-analysis of four clinical trials shows that taking probiotics during pregnancy increases the relative risk of pre-eclampsia.
The specific effects of Bifidobacterium animalis ssp lactis (B-420™) are unclear from this analysis.
Pack: 60 Capsules
Ultra Flora MetaControl have been shown to or may:
Provides metabolic benefits including reduced Body Mass Index (BMI), reduction in total cholesterol and Low Density Lipoprotein (LDL).
Improves weight management including total and abdominal fat mass, waist circumference and reduced energy intake.
Clinical Benefits:
Recent microbiome research has established a potential correlation between body weight and the microbiome. DNA analysis has shown that obese subjects may have a different microbiome composition to lean subjects. Gut bacterial composition is able to influence how energy is stored, as well as influence glycaemic control and satiety hormones. Specific probiotics can be a useful adjunct to dietary programs to control weight, metabolic markers and body composition.
Weight control and body composition: Bifidobacterium animalis ssp lactis (B-420™) has a growing body of human and animal research, including a 2016 clinical trial. A 6 month study of 225 non-dieting, overweight people (predominantly women aged 40+) took 10 billion CFU B-420™ daily (with or without dietary fibre) or placebo. Both B-420™ groups showed significant improvements in fat mass, abdominal fat, waist circumference and lean muscle mass, as well as an overall reduction in calorie consumption. Pre-clinical animal and in vitro research on B-420™ has demonstrated reduced weight gain, improved glycaemic response, reduced zonulin levels (a marker of intestinal permeability), improved tight junction integrity, and protection against E. coli-induced damage; decreasing gut inflammation and the consequential impairment in insulin sensitivity.
Cardiometabolic markers can also be influenced by probiotics. A 2016 study on 51 adults with metabolic syndrome showed that Bifidobacterium animalis ssp lactis (HN019™) reduced BMI, total cholesterol (TC) and low density lipoprotein (LDL). The proposed mechanism is associated with prevention of cholesterol absorption by the intestinal tract into the blood stream, by aiding the assimilation of cholesterol during bacterial multiplication and cholesterol binding, and to improve liver metabolism through increased short chain fatty acid (SCFA) production, inhibiting HMG Co-A reductase. Mechanistically, it has been shown to reduce proinflammatory cytokines TNF-α and IL-6, which are associated with the development of obesity.
*27.2 Billion CFU daily of HN019™equivalent to two capsules
Directions:
Adults: Take 1 capsule daily.
Storage:
Store at 2°C to 8°C (Refrigerate. Do not freeze.)
Warnings:
As a precaution: Safety has not been conclusively established during pregnancy. Practitioner discretion is advised when prescribing for use in pregnancy due to the following cautions:
Pre-eclampsia: A meta-analysis of four clinical trials shows that taking probiotics during pregnancy increases the relative risk of pre-eclampsia.
The specific effects of Bifidobacterium animalis ssp lactis (B-420™) are unclear from this analysis.
Pack: 60 Capsules
